Sarah Kantelis, PA
Psychiatric/Mental Health · Mission Viejo, CANPI 1881047892
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,064 of the $24,877 with a category attached, or 84.7%. 31 manufacturers reported payments, led by AbbVie at 27.7% of the total. 2025 is the largest year on record at $8,807, 4.7 times the $1,864 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 897 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Johnson & Johnson$2K
- Vanda Pharmaceuticals Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Supernus Pharmaceuticals, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $9K from 25 others
What the payments were for
- Speaking & faculty fees$3,75015%
- Food & beverage$21,06485%
- Education$630%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 140 | $6,884 |
| Johnson & Johnson | 73 | $2,429 |
| Vanda Pharmaceuticals Inc. | 69 | $2,064 |
| Otsuka America Pharmaceutical, Inc. | 98 | $1,908 |
| Supernus Pharmaceuticals, Inc. | 57 | $1,604 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,445 |
| Neurocrine Biosciences, Inc. | 48 | $1,144 |
| Teva Pharmaceuticals USA, Inc. | 41 | $1,054 |
| Alkermes, Inc. | 50 | $992 |
| Lundbeck LLC | 35 | $653 |
| Axsome Therapeutics, Inc. | 20 | $604 |
| Sunovion Pharmaceuticals Inc. | 25 | $550 |
| E.r. Squibb & Sons, L.L.C. | 17 | $474 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $463 |
| Ironshore Pharmaceuticals Inc. | 16 | $351 |
| Corium, LLC | 16 | $324 |
| Almatica Pharma LLC | 15 | $309 |
| Indivior Inc. | 12 | $273 |
| Noven Therapeutics, LLC | 9 | $176 |
| Tris Pharma Inc | 3 | $160 |
| Avanir Pharmaceuticals, Inc. | 7 | $153 |
| Bausch Health US, LLC | 7 | $144 |
| OWP Pharmaceuticals, Inc. | 7 | $138 |
| Acadia Pharmaceuticals Inc | 4 | $97 |
| Livanova USA, Inc. | 5 | $96 |
| Eisai Inc. | 6 | $93 |
| Merck | 6 | $90 |
| Collegium Pharmaceutical, Inc. | 4 | $83 |
| Biogen | 3 | $80 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Adlon Therapeutics L.p. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$4,110
- SPRAVATO$274
- QELBREE$246
- REXULTI$221
- Austedo XR$120
- Dyanavel XR$120
- AUSTEDO$119
- INVEGA SUSTENNA$117
- Auvelity$112
How this compares
$24,877 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 19 | $27,759 |
| TrintellixVortioxetine Hydrobromide | 16 | $8,848 |
| Duloxetine Hcl | 80 | $1,121 |
| Trazodone Hcl | 39 | $609 |
| Quetiapine Fumarate | 32 | $545 |
| Bupropion XlBupropion Hcl | 38 | $533 |
| Hydroxyzine Pamoate | 36 | $484 |
| Mirtazapine | 27 | $363 |
| Olanzapine | 21 | $314 |
| Prazosin Hcl | 27 | $292 |
| Lamotrigine | 25 | $201 |
| Aripiprazole | 17 | $201 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $192 |
| Lithium Carbonate | 12 | $172 |
| Buspirone Hcl | 24 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $6,884 | $27,75919 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $463 | $8,84816 claims |
| Almatica Pharma LLCSertraline Hcl | $309 | $7118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Mission Viejo
- Krista FendrickMission Viejo$14K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.